Testing a combination of two new drugs for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests two new investigational drugs, JANX013 and JANX007, together in men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man who is at least 18 years old.
- You must have confirmed prostate cancer (adenocarcinoma).
- You must have already been treated with at least one hormone therapy (like abiraterone, enzalutamide, apalutamide, or darolutamide).
- You must either have had chemotherapy with a taxane (like docetaxel), or be unable to take or have refused taxane chemotherapy.
- You cannot have had certain previous treatments (CAR T-cell therapy, T-cell engagers, or T-cell costimulatory agents).
- You cannot have significant heart disease or have had an organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new immunotherapy drug called JANX014 in men with advanced prostate cancer that has stopped responding to hormone treatments. The trial aims to find the right dose and see if this drug can help slow or stop cancer growth.
This Phase 1 trial tests JANX007 in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite standard hormone treatment). It aims to find a safe dose and see whether the treatment can shrink tumors or slow progression.
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
This trial tests a new drug called KTX-2001, possibly combined with another drug (darolutamide), for men whose prostate cancer has spread and stopped responding to standard hormone treatments. The goal is to see if it can help shrink tumors or slow the cancer's growth.
This study tests a combination of two new investigational drugs for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drugs aim to help your immune system fight the cancer cells.
This trial tests a new combination of two study drugs for people with advanced prostate cancer that has spread or is no longer responding to hormone therapy. The goal is to see if the combination is safe and works against the cancer.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.